【作者】 曹帅；

【导师】 张成武；

【作者基本信息】 青海大学 ， 外科学， 2015， 硕士

【摘要】 目的:探讨胃癌手术患者新辅助化疗DCF方案和FOLFOX6方案的疗效。方法:采用FOLFOX6和DCF联合用药方案对患者进行有效化疗,评估化疗疗效。结果:FOLFOX6组和DCF组的临床控制率分别为38.9%、70.0%,差异有统计学意义(P<0.05)。两种化疗方案比较DCF组降期有效率较高,差异有统计学意义(P<0.05)。由于样本有限,DCF组和FOLFOX6组的R0切除率,术后并发症发生率差异不明显,差异无统计学意义。结论:对胃癌手术患者进行评估和新辅助化疗,是提高患者生存质量的有效方法。规定的样本内,在临床控制率和降期有效率方面,DCF方案高于FOLFOX6方案,但是化疗后不良反应比较,DCF方案化疗后白细胞减少和腹泻发生率明显较高(P<0.05),提示DCF方案在明显有效性的同时也存在较为严重的毒性,启发我们在选择化疗方案时,考虑临床作用的同时也应该考虑到患者的耐受性。更多还原

【Abstract】 Objective: To evaluate the effect of operation in patients with gastric cancer D C F scheme and FOLFOX6 scheme. Methods: Taking FOLFOX6 and DCF regimen for patients with effective chemotherapy to evaluate the efficacy of chemotherapy. Results: The clinical control rate of FOLFOX6 group and DCF group are 38.9% and 70.0%,(P < 0.05). Comparison of the two chemotherapy groups,DCF groups can more effectively reduce the staging,the difference is statistically significant(P <0.05). Because of small sample size, the two groups of radical resection rate and postoperative complications do not differ significantly, the difference is not statistically significant(P >0.05). Conclusion: Patients should be evaluated for gastric surgery and neoadjuvant chemotherapy, to improve the quality of life in patients with an effective way.Within the sample prescribed,In clinical control rate and lowering of the effective rate, DCF scheme is more obvious than FOLFOX6 program, but DCF scheme has more toxic,which inspired us in the choice of chemotherapy, considering the clinical effects should also take into account the patient’s tolerance.更多还原